Methods All observational studies evaluating the prognosis of HIV-positive patients treated with PCI were included. Inhospital and long-term major adverse cardiac events (MACE) [composite endpoint of all-cause death or myocardial infarction (MI)] were the primary endpoints, whereas inhospital and long-term all-cause death, cardiovascular death, MI, stent thrombosis, target vessel revascularization (TVR), target lesion revascularization (TLR), and bleeding complications were the secondary ones.
Findings In all, 1243 patients in nine studies were included, with a mean age of 54 years. Among them, 12% were female and 91% were admitted for acute coronary syndromes. Inhospital MACE occurred in 6.0% (5.4-6.6), death in 4.2% (2.6-5.9), and MI in 1.3% (0-2.8), whereas major bleeding occurred in 2.0% (1.7-2.3) of the patients. After 2 years (1.6-3.1), long-term MACE occurred in 17.4% (11.9-22. 3), all-cause death in 8.7% (3.2-14.2) , and MI in 7.8% (5.5-10.1) of the patients, whereas stent thrombosis and TVR in 3.4% (1.5-5.3) and 10.5% (7.5-13.4), respectively. In patients treated with drug-eluting stents (DES), the rate of long-term MACE was 22.3% (10.1-34.4), with an incidence of 4.9% (0.0-11.4) of MI and 5.7% (2.3-13.7, all 95% confidence intervals of TLR.
Interpretation HIV-positive patients have a high risk of inhospital and long-term MACE after PCI, partially reduced by the use of DES. Further studies on the risk of recurrent ischemic events with current generation stents are needed, to offer a tailored therapy in this high-risk population.
Introduction
Globally, almost 3 million people in the world live with HIV nowadays, and 0.8% of adults aged 15-49 years have the infection. Sub-Saharan Africa is the most severely affected area, with 1 out of every 25 adults (4.4%) infected by the virus, whereas about 2.2 million people are infected in North America, and Western and Central Europe.
1 Antiretroviral therapies dramatically reduced the morbidity and mortality associated with HIV. 2 As a result, life expectancy increased, and morbidities, which historically were not related to HIV, became more frequent in this population. Among them, cardiovascular diseases (CVDs) are one of the most significant health issues encountered in HIV-positive patients. 3 Pathogenesis of cardiovascular disease in HIV-positive patients is related to the interactions occurring between traditional risk factors, the HIV infection itself, and the highly active antiretroviral therapy (HAART), which still plays a controversial role. [4] [5] [6] [7] [8] [9] [10] [11] These patients, when presenting with coronary artery disease (CAD), often have unstable atheromatous plaques, leading to increased risk of recurrence at long term, despite treatment with percutaneous coronary intervention (PCI), due to accelerated atherosclerosis both on previously treated and de-novo vessels.
Two major issues remain to be clarified, which are as follows:
1) In-hospital events for HIV-positive patients treated with PCI: Being usually younger, their periprocedural risk is perceived as lower to that of other patients. Despite this, their increased thrombotic risk 4 may positively interact with the pro-coagulative status typical of an acute coronary syndrome (ACS) or of a PCI for stable CAD, complicated by periprocedural myocardial infarction (MI). 12 2) Long-term safety of drug-eluting stents (DES): In the general population, DES have been shown to be superior to bare metal stents (BMS) in terms of restenosis, without increased risk of stent thrombosis. 13, 14 In HIV-positive patients, a high risk of stent thrombosis has been largely described, 4 although only limited data have been provided about differences between BMS and first-or second-generation DES.
Consequently, we performed a meta-analysis of observational studies to investigate the short-and long-term outcomes of HIV-positive patients undergoing PCI, in the setting of both acute and chronic ischemic heart disease.
Methods
The present study was performed according to current guidelines, including the recent Preferred Reporting Items for Systematic reviews and Meta-Analyses amendment to the Quality of Reporting of Meta-analyses (PRISMA) statement and recommendations from The Cochrane Collaboration and Meta-analysis of Observational Studies in Epidemiology (MOSE). [15] [16] [17] Search and inclusion criteria Three authors, (M.P., R.V. and F.D.A.), independently from each other, searched PubMed, Medline, Embase, Cochrane, and Google Scholar with Mesh strategy for the following terms: ('HIV' or 'human immunodeficiency virus') AND ('stent' or 'percutaneous coronary intervention' or 'PCI' or 'percutaneous revascularization'). Studies appraising only HIV-positive patients or HIV-positive and HIV-negative patients were included.
All studies were independently reviewed, with disagreements resolved by consensus. Inclusion criteria were as follows: human studies; HIV-positive patients presenting with ACS or stable coronary syndrome; studies evaluating patients treated with percutaneous revascularization, whereas exclusion criteria were: nonhuman settings; duplicate reporting (in which case the manuscript reporting the largest sample of HIV-positive patients).
Data abstraction
The following data were independently abstracted by three authors (M.P., R.V. and F.D.A.) on prespecified electronic forms: authors, journal, year of publication, baseline features (in particular age, risk factors and medical history), HIV-related features (CD4 levels, duration of HIV infection, types of antiretroviral drugs), procedural features (indication of PCI, types of coronary stents). The corresponding authors of the relevant studies were queried for required quantitative details not in the published manuscripts.
Endpoints Long-term major adverse cardiac events (MACE) (a composite endpoint of all-cause death or MI) was the primary endpoint, whereas all-cause death, cardiovascular death, MI, stent thrombosis, target vessel revascularization (TVR) and target lesion revascularization (TLR), and in-hospital MACE were the secondary ones. Subgroup analysis was performed for types of stents (BMS vs. DES) and for in-hospital outcomes (MACE, all-cause death, cardiovascular death, MI, recurrent angina, stroke, and bleeding complications).
Quality study evaluation
The quality of the studies which were included was independently appraised by three reviewers (M.P., R.V. and F.D.A.), with disagreements resolved by consensus. We have modified the MOOSE 18 items, to take into account the specific features of the studies that were included, and separately abstracted and appraised the study design, setting, data source, and also the risk of analytical, selection, adjudication, detection, and attrition bias (expressed as low, moderate, or high risk of bias, and also incomplete reporting leading to inability to ascertain the underlying risk of bias). Information regarding the design of the study (multicenter or not), area of enrollment, and kind of multivariate analysis was collected.
Statistical analysis
Continuous variables are reported as mean (SD) or median (first and third quartiles). Categorical variables are expressed as n (%). Statistical pooling for incidence estimates was performed according to a random-effect model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals (CIs), using RevMan 5.2 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Hypothesis testing for superiority was set at the twotailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the two-tailed 0.10 level and based on the Cochrane Q test, with I 2 values of 25, 50, and 75% representing mild, moderate, and severe heterogeneity, respectively.
Results
A total of 161 records were identified, of which 9 studies were finally included, after screening and full-text assessment: 7 of them were prospective observational studies, whereas 2 were retrospective observational studies (see appendix, Fig. 1 , http://links.lww.com/JCM/A152).
In all, 1243 patients were included in the analysis for the primary endpoint, 8724 patients were included in the analysis for the in-hospital outcomes, and only 209 patients were included in the subgroup analysis for stent type (Tables 1-4 (Table 1) .
Regarding anatomical characteristics of CAD, more than 50% of the patients presented with a multivessel disease. Left anterior descending artery (LAD) was the most commonly affected vessel (40.6%: 39.8-43.2), followed by the right coronary (RCA) (30.6%: 28.0-30.7) and circumflex arteries (25.3%: 23.0-25.3), whereas 1.4% (0.6-3.6) of patients had left main disease. PCI was performed with DES in 49% (41.8-57.8) of the patients (Table 2) . Unfortunately, there were not sufficient data regarding the duration of the dual antiplatelet therapy (DAPT), because only one study reported this information.
With respect to in-hospital outcomes, MACE occurred in 6.0% (5.4-6.6), death in 4.2% (2.6-5.9), and MI in 1.3% (0.0-2.8) of the patients; the first with a low heterogeneity index (I 2 0%), the second with a higher one (I 2 71%). As for in-hospital complications, stroke occurred in 1.4% (1.1-1.7; I 2 index 0%), whereas major bleeding was observed in 2.0% (1.7-2. Regarding the quality of the studies that were included (see appendix, Table 2 , http://links.lww.com/JCM/A152), four of them were multicenter, with low/moderate risk of evaluated bias.
Discussion
To the best of our knowledge, this is the largest metaanalysis investigating the in-hospital and long-term outcomes of HIV-positive patients undergoing PCI.
The main results are as follows:
(1) HIV-positive patients had a high rate of in-hospital and long-term MACE, in particular with regard to the young age of the patient population. Nowadays, HIV-positive patients live longer than before, mostly due to a more effective antiretroviral therapy. The increased life expectancy of such patients has been matched with an increased burden of chronic conditions, such as CAD. Moreover, specific factors contribute to unique pathogenesis in these patients, culminating in accelerated development of atherosclerosis, thought to be related to a complex interaction between traditional risk factors, and infection-related and therapy-related factors. However, the specific contribution of each component to the augmented risk is not yet fully understood. 16 An increased prevalence of high-risk atherosclerotic plaques, prone to destabilization, has been described in these patients. There is also emerging evidence to indicate that HIV infection and the subsequent inflammatory processes, highlighted by increased interleukin-6 production, accelerate atherogenesis in humans. [19] [20] [21] Furthermore, the prothrombotic diathesis increases proportionally to the viral load, and the CD4 cell count drops. 21 Several studies have also shown that the HIV virus contributes to these effects by penetrating the endothelial cell membrane and inducing intracellular inflammatory responses. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Shifting from bench to bedside, observational studies involving a larger number of HIV-positive patients showed an increased incidence of MI in association with a longer exposure to antiretroviral therapies. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Our meta-analysis showed an overall average incidence of traditional cardiovascular risk factors, as can be expected in a young population. In particular, HIV-positive patients showed higher percentages of hypertriglyceridemia compared with the general population. [29] [30] [31] Revascularization strategies in case of ACS were the same as for the general population.
In our meta-analysis, high rates of long-and short-term MACE after revascularization were demonstrated, probably due to the high rates of ACS as the clinical presentation, and to the high exposure to protease inhibitors and NRTIs. Regarding short-term outcomes, we reported an incidence of death of 4.2% and of MI of 1.3%. Studies in the general population reported lower rates of cardiovascular in-hospital events after ACS; as an example, in a substudy of the Global Registry of Acute Coronary Events, analyzing more than 4000 patients aged 44-54 years, who were hospitalized for ACS, the incidence of in-hospital mortality and stroke was 2.0 and 0.5%, respectively. 32 Our results stress the importance of careful clinical observation in HIV-positive patients hospitalized for ACS. Given the augmented short-term risk, it could be reasonable, in specific cases, to maintain a longer and more intensive monitoring than in the general population. Regarding long-term outcomes, our meta-analysis confirmed that HIV-positive patients have a high burden of stent thrombosis and recurrent revascularization, at rates of 3.4 and 10.5%, respectively, with a median followup of 2 years. Regarding HIV-negative population, the Dutch Stent Thrombosis Registry analyzed the incidence of stent thrombosis in more than 20,000 patients treated with BMS or DES: the overall incidence of stent thrombosis was 2.1%. 33 Our findings could be partly explained by the prothrombotic state, which may trigger the higher incidence of MI, related both to progression of disease and to stent thrombosis. 34 Dual antiplatelet therapy length and type of antiplatelet drug used are a major determinant of stent thrombosis. Unfortunately, results on DAPT duration and type of antiplatelet drugs were not available, as only one study included such data. 35 Multiple drug interactions have been reported with the use of antiretroviral drugs. 36 In a study on immunosuppressive therapy, it was demonstrated that protease inhibitors increase the sirolimus plasma concentration, and this could generate an increased stent endothelization time, resulting in an increased risk of ST. 37 A similar effect could be possible when using paclitaxel-covered stents. Furthermore, pharmacokinetic interactions were reported with the new P2Y12 inhibitors (prasugrel and ticagrelor) and antiretroviral therapy, which may partially explain the increased risk of events in HIV-positive patients. 38 Myocardial infarction and TLR were more frequent in HIV-positive patients treated with BMS (8.8 vs. 4.9% and 21.1 vs. 5.7%, respectively), suggesting potential benefits with the use of DES. 30 In the general population, the Swedish Coronary Angiography and Angioplasty Registry reported an incidence of MI of 11.6% for BMS and of 11.5% for DES, whereas restenosis was 4.4% in the BMS group vs. 2.9% in the DES group. 39 A separate study of more than 2000 HIV-negative patients treated with PCI reported an incidence of TLR of 9.2% in patients treated with BMS vs. 4.5% in patients treated with DES. 40 In summary, although these findings are in an observational and nonrandomized setting, the benefits of DES use were even greater in HIV-positive patients than in the general population. Notably, DES were deployed in only 49% of the HIV-positive patients. A possible explanation of this finding could be a higher perceived risk of bleeding events in this population among interventional cardiologists.
Intracoronary imaging such as optical coherence tomography (OCT) or intravascular ultrasound (IVUS) is, at present, a valuable option both for diagnosis and optimization of interventional results. However, although its role in the general population has been established, few studies reported data on its use in HIV patients. 41 Given the above mentioned results, interventional cardiologists should consider multiple aspects when dealing with CAD in these patients, to minimize the risk of ST:
(1) Prefer the use of DES unless contraindicated, given the potential benefit for short-and long-term thrombotic events. (2) Adopt special care in avoiding known risk factor for ST: stent under-expansion, implantation of long stents, use of multiple stents, incomplete lesion coverage, persistent slow flow, residual stenosis, and dissections of the vessel. (3) The possibility of using intracoronary imaging, such as OCT or intravascular ultrasound (IVUS), to ensure an optimized deployment of stents, especially in patients with a complex coronary anatomy. (4) Given the high recurrence rate of MACE, the importance of a full-length DAPT and, in specific cases, the possibility of considering a prolongation of DAPT.
Limitations
Our work has several limitations. First, the results of the present analysis werea derived neither from randomized clinical trials nor from multivariate adjustments. Second, only two studies compared the outcomes stratified according to the kind of implanted stents (DES vs. BMS), so further analysis, with randomized controlled trials, is necessary. Third, because the vast majority of the patients were hospitalized in acute settings, with a greater thrombotic burden, our results are of limited translation into clinical practice for stable patients. Publication bias was low (see appendix, Fig. 11 , http://links.lww.com/ JCM/A152).
Conclusions
With the progressive increase in life expectancy, thanks to HAART, HIV-positive patients are faced with increased burden of comorbidities, particularly cardiovascular diseases. Despite the evidence-based management of CVD in these patients, including revascularization strategies that follow the guidelines of the general population, this subgroup had an increased rate of MACE during this follow-up period. There seems to be a positive effect of the utilization of DES in these patients, but further studies, including randomized controlled trials, are necessary, to guide us on the proper management of HIV-positive patients with CAD.
